Dr. Judge is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
171 Ashley Ave
Charleston, SC 29425Phone+1 843-792-1414
Summary
- I am a board-certified specialist in Advanced Heart Failure & Transplant Cardiology, also boarded in Cardiovascular Disease. I direct the Cardiovascular Genetics program at Medical University of South Carolina, and I am also the Fellowship Program Director for Cardiovascular Disease at MUSC in Charleston, SC.
Education & Training
- Johns Hopkins UniversityFellowship, Cardiovascular Disease, 1996 - 2000
- Johns Hopkins UniversityResidency, Internal Medicine, 1993 - 1996
- Perelman School of Medicine at the University of PennsylvaniaClass of 1992
Certifications & Licensure
- SC State Medical License 2018 - 2025
- MD State Medical License 1996 - 2018
- American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
- American Board of Internal Medicine Cardiovascular Disease
Clinical Trials
- DCM Precision Medicine Study Start of enrollment: 2016 Jun 07
Publications & Presentations
PubMed
- Alcohol Exposure Among Patients With Dilated Cardiomyopathy and Their First-Degree Relatives: The DCM Precision Medicine Study.Javier Jimenez, Hanyu Ni, Stuart D Katz, Garrie J Haas, Jinwen Cao
Circulation. Genomic and Precision Medicine. 2025-03-28 - 1 citationsEfficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.Daniel P Judge, Kevin M Alexander, Francesco Cappelli, Marianna Fontana, Pablo Garcia-Pavia
Journal of the American College of Cardiology. 2025-03-18 - 2 citationsLong-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.Daniel P Judge, Julian D Gillmore, Kevin M Alexander, Amrut V Ambardekar, Francesco Cappelli
Circulation. 2025-03-04
Press Mentions
- BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific SessionsMarch 24th, 2025
- FDA Approves Acoramidis, BridgeBio’s New ATTR-CM DrugNovember 23rd, 2024
- New ATTR-CM Drug Linked to Positive Long-Term Data as FDA Nears Final DecisionNovember 22nd, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: